Philip J. Stephens

United States Department of the Navy

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index105

i10-index309

Publications711

Citations78,257

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last latest available · showing 20 of 182

Supplementary Methods from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsPreprint
2023-04-03
Supplementary Table S3 from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
2023-04-03
Supplementary Figure 2 from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsPreprint
2023-04-03
Data from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET InhibitorsPreprint
2023-04-03
Supplementary Figure 1 from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsPreprint
2023-04-03
Supplementary Table S3 from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
2023-04-03
Supplementary Figure Legends, Table Legends from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsPreprint
2023-04-03
Data from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsPreprint
2023-04-03
Supplementary Figure 1 from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsPreprint
2023-04-03
Data from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsPreprint
2023-04-03
Supplementary Figure Legends, Table Legends from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsPreprint
2023-04-03
Supplementary Table 2 from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
2023-04-03
Supplementary Table 1 from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
2023-04-03
Supplementary Table S4 from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
2023-04-03
Data from Concordance of Genomic Alterations between Primary and Recurrent Breast CancerPreprint
2023-04-03
Supplementary Methods from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase FusionsPreprint
2023-04-03
Supplementary Table S1 from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
2023-04-03
Supplementary Table S1 from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
2023-04-03
Data from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET InhibitorsPreprint
2023-04-03
Supplementary Table 3 from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
2023-04-03

Open author page on OpenAlex →